Published in

Future Medicine, Future Oncology, 19(16), p. 1371-1384, 2020

DOI: 10.2217/fon-2020-0039

Links

Tools

Export citation

Search in Google Scholar

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Journal article published in 2020 by Malou Cp Kuppen ORCID, Hans M. Westgeest ORCID, Maarten J. van der Doelen, Alphonsus Jm van den Eertwegh, Jules Llm Coenen, Katja Kh Aben ORCID, Alphons Cm van den Bergh, Andries M. Bergman, Joan van den Bosch, Filiz Celik, Mathijs P. Hendriks ORCID, Jules Lavalaye, Saskia van der Meer, Marco B. Polee, Diederik M. Somford and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689–6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014–2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.